Emergent BioSolutions (EBS) Non-Current Deferred Tax Liability (2013 - 2026)
Emergent BioSolutions (EBS) posted quarterly Non-Current Deferred Tax Liability of $33.3 million for Q1 2026, down 44.87% year-over-year from $60.4 million in Q1 2025, and down 11.9% quarter-over-quarter from $37.8 million in Q4 2025.
Emergent BioSolutions (EBS) Non-Current Deferred Tax Liability (2013 - 2026) Analysis & Trends
Emergent BioSolutions' Non-Current Deferred Tax Liability history runs 11 years deep, the most recent figure standing at $33.3 million for Q1 2026.
- In Q1 2026, Non-Current Deferred Tax Liability fell 44.87% year-over-year to $33.3 million; the TTM figure through Mar 2026 stood at $33.3 million (down 44.87% YoY), while the FY2025 annual figure was $37.8 million, down 9.35% from the prior year.
- Non-Current Deferred Tax Liability for Q1 2026 stood at $33.3 million, down from $37.8 million in the prior quarter.
- The five-year high for Non-Current Deferred Tax Liability was $125.4 million in Q4 2022, with the low at $33.3 million in Q1 2026.
- The 5-year median for Non-Current Deferred Tax Liability is $47.2 million (2023), against an average of $59.5 million.
- The sharpest annual moves came in 2022 and 2023: Non-Current Deferred Tax Liability surged 114.91% in 2022, then slumped 62.36% in 2023.
- Emergent BioSolutions' Non-Current Deferred Tax Liability stood at $125.4 million in 2022, then plunged by 62.36% to $47.2 million in 2023, then declined by 11.65% to $41.7 million in 2024, then dropped by 9.35% to $37.8 million in 2025, then fell by 11.9% to $33.3 million in 2026.
- Business Quant data shows EBS's Non-Current Deferred Tax Liability at $33.3 million in Q1 2026, $37.8 million in Q4 2025, and $36.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | Emergent BioSolutions | 261.35 Mn | 120.45 Mn | 137.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 35.40 Mn |
| Jun 30, 2026 | 35.40 Mn |
| Mar 31, 2026 | 33.30 Mn |
| Mar 31, 2026 | 33.30 Mn |
| Dec 31, 2025 | 37.80 Mn |
| Dec 31, 2025 | 37.80 Mn |
| Sep 30, 2025 | 36.30 Mn |
| Sep 30, 2025 | 36.30 Mn |
| Jun 30, 2025 | 46.50 Mn |
| Jun 30, 2025 | 46.50 Mn |
| Mar 31, 2025 | 60.40 Mn |
| Mar 31, 2025 | 60.40 Mn |
| Dec 31, 2024 | 41.70 Mn |
| Dec 31, 2024 | 41.70 Mn |
| Sep 30, 2024 | 41.90 Mn |
| Sep 30, 2024 | 41.90 Mn |
| Jun 30, 2024 | 34.80 Mn |
| Jun 30, 2024 | 34.80 Mn |
| Mar 31, 2024 | 34.80 Mn |
| Mar 31, 2024 | 34.80 Mn |